392721-37-8

中文名稱 N-[4-chloro-3-(trifluoromethyl)phenyl]-3-oxobutanamide

英文名稱 N-[4-chloro-3-(trifluoromethyl)phenyl]-3-oxobutanamide

CAS 392721-37-8

分子式 C11H9ClF3NO2

分子量 279.64

MOL 文件 392721-37-8.mol

更新日期 2024/04/08 11:57:26

392721-37-8 結構式

基本信息物理化學性質安全數(shù)據(jù) N-[4-chloro-3-(trifluoromethyl)phenyl]-3-oxobutanamide價格(試劑級) 常見問題列表

基本信息

中文別名

化合物FASENTIN
N-(4-氯-3-(三氟甲基)苯基)-3-氧代丁酰胺

英文別名

Fasentin
Fasentin NEW
Fasentin >=98% (HPLC)
Fasentin - CAS 392721-37-8 - Calbiochem
N-[4-chloro-3-(trifluoromethyl)phenyl]-3-oxobutanamide

物理化學性質

儲存條件room temp

溶解度二甲基亞砜：>10mg/mL

形態(tài)粉末

顏色白色至灰白色

穩(wěn)定性DMSO中的溶液可在-20°下穩(wěn)定儲存3個月。

安全數(shù)據(jù)

危險性符號(GHS) GHS hazard pictograms

GHS07

警示詞警告

危險性描述H302

防范說明P264-P270-P301+P312-P330-P501

危險品標志Xn

危險類別碼22

WGK Germany3

N-[4-chloro-3-(trifluoromethyl)phenyl]-3-oxobutanamide價格(試劑級)

報價日期	產(chǎn)品編號	產(chǎn)品名稱	CAS號	包裝	價格
2024/11/08	HY-101849	N-[4-chloro-3-(trifluoromethyl)phenyl]-3-oxobutanamide Fasentin	392721-37-8	5mg	700元
2024/11/08	HY-101849	N-[4-chloro-3-(trifluoromethyl)phenyl]-3-oxobutanamide Fasentin	392721-37-8	10mM * 1mLin DMSO	770元
2024/11/08	HY-101849	N-[4-chloro-3-(trifluoromethyl)phenyl]-3-oxobutanamide Fasentin	392721-37-8	10mg	1100元

常見問題列表

生物活性

Fasentin 是有效的葡萄糖攝取抑制劑，可抑制 GLUT-1/GLUT-4 轉運蛋白。Fasentin 優(yōu)先抑制 GLUT4 (IC50=68 μM)。Fasentin 是死亡受體刺激 (FAS) 敏化劑，可敏化細胞對 FAS 誘導的細胞死亡。Fasentin 也是誘導腫瘤壞死因子 (TNF) 凋亡配體的敏化劑。Fasentin 阻斷癌細胞系中的葡萄糖攝取，并具有抗血管生成活性。

靶點

GLUT4

68 μM (IC ₅₀ )

GLUT1

體外研究

Fasentin (0.1-1000 μM; 72?hours) inhibits endothelial, tumour and fibroblast cell growth without inducing cell death.
Fasentin (25-100 μM; 16-24 hours) induces a cell cycle arrest in G0/G1 phase and reduces the cell number in S phase in a dose-dependent manner.
Fasentin (50 μM; 16 hours) alters expression of genes associated with glucose deprivation such as AspSyn and PCK-2.
Fasentin (15, 30, 80 μM; pretreatment 1 hour) induces glucose deprivation, partially blocks glucose uptake in PPC-1, DU145, and U937 cells.
Fasentin (100 μM; 16 hours) does not affect the migratory capability of endothelial cells.
Fasentin (25-100 μM; 16?hours) lowers levels of phospho-ERK in HMECs, indicating a partial inhibition on the ERK signalling pathway, even though the effect is not statistically significant. Fasentin does not inhibit the tyrosine kinase activity of VEGFR2.
Fasentin interacts with a unique site in the intracellular channel of GLUT1.

Cell Viability Assay

Cell Line:	Three types of endothelial cells ECs (HMEC, human microvascular endothelial cells; HUVEC, human umbilical vein endothelial cells; and BAEC, bovine aortic endothelial cells), three human tumour cell lines (MDA-MB-231 and MCF7 breast carcinoma cells, and HeLa cervix adenocarcinoma cells), and human gingival fibroblasts (HGF)
Concentration:	0.1, 1, 10, 100, 1000 μM
Incubation Time:	72?hours
Result:	Inhibited endothelial, tumour and fibroblast cell growth (IC ₅₀ =26.3-111.2 μM) without inducing cell death.

Cell Cycle Analysis

Cell Line:	HMECs
Concentration:	25, 50, 100 μM
Incubation Time:	16, 24 hours
Result:	Induced a cell cycle arrest in G0/G1 phase and reduced the cell number in S phase in a dose-dependent manner. Did not increase the subG1 population.

RT-PCR

Cell Line:	PPC-1 cells ^[2]
Concentration:	50 μM
Incubation Time:	16 hours
Result:	Altered expression of genes associated with glucose deprivation such as AspSyn and PCK-2 not FLIP mRNA expression.